Terms: = Endocrine gland cancer AND Ki-67 AND Treatment
590 results:
1. A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma.
Tang H; Miao X; Yu C; Chai C; Su Y; Li L; Yi J; Ye Z; Miao L; Wang Z; Zhang H; Xu H; Zhou W
Sci Rep; 2024 Apr; 14(1):9259. PubMed ID: 38649719
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical features of patients with metastatic pheochromocytoma/paraganglioma].
Cui YY; Zhou Y; Gao YJ; Li TY; Wang Y; Zhang WQ; Zhou T; Chen S; Tong AL
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1174-1179. PubMed ID: 38583049
[No Abstract] [Full Text] [Related]
3. Podocalyxin promotes the formation of compact and chemoresistant cancer spheroids in high grade serous carcinoma.
Le Tran N; Wang Y; Bilandzic M; Stephens A; Nie G
Sci Rep; 2024 Mar; 14(1):7539. PubMed ID: 38553472
[TBL] [Abstract] [Full Text] [Related]
4. Self-assembled nanomicelles for oral delivery of luteolin utilizing the intestinal lymphatic pathway to target pancreatic cancer.
Karole A; Dinakar YH; Sagar P; Mudavath SL
Nanoscale; 2024 Apr; 16(15):7453-7466. PubMed ID: 38517408
[TBL] [Abstract] [Full Text] [Related]
5. Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection.
Olearska H; Sowa-Staszczak A; Morawiec-Sławek K; Kurzyńska A; Kolasa M; Tkacz E; Szumińska M; Hubalewska-Dydejczyk A; Opalinska M
Endokrynol Pol; 2024; 75(1):102-108. PubMed ID: 38497396
[TBL] [Abstract] [Full Text] [Related]
6. EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer.
Yang Z; Chen F; Wei D; Chen F; Jiang H; Qin S
BMC Cancer; 2024 Feb; 24(1):268. PubMed ID: 38408959
[TBL] [Abstract] [Full Text] [Related]
7. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
8. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract] [Full Text] [Related]
9. [Antitumor effects of redox-responsive nanoparticles containing platinum（Ⅳ）in ovarian cancer].
Hou HY; Tang DS; Zhang YN; Wang KY; Ao M; Luo HX; Li B
Zhonghua Zhong Liu Za Zhi; 2024 Jan; 46(1):76-85. PubMed ID: 38246783
[No Abstract] [Full Text] [Related]
10. Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of Japan.
Nakanishi S; Fukushima Y; Inokuchi J; Hakariya T; Kakinoki H; Enokida H; Chikui K; Matsuoka H; Shin T; Mukai S; Kamba T; Eto M; Imamura R; Noguchi M; Igawa T; Haga N; Kamoto T; Fujimoto N; Saito S
Int J Urol; 2024 May; 31(5):484-491. PubMed ID: 38193650
[TBL] [Abstract] [Full Text] [Related]
11. Patterns of treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
[TBL] [Abstract] [Full Text] [Related]
12. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract] [Full Text] [Related]
13. Asiaticoside Down-Regulates HIF-1α to Inhibit Proliferation, Migration, and Angiogenesis in Thyroid cancer Cells.
Zhang Y; Han Y; Dong J; Li F; Sun Y
Balkan Med J; 2024 Jan; 41(1):23-29. PubMed ID: 38044598
[TBL] [Abstract] [Full Text] [Related]
14. Characteristics and treatment options of glucagonomas: a national study from the French Group of endocrine Tumors and ENDOCAN-RENATEN network.
Perrier M; Brugel M; Gérard L; Goichot B; Lièvre A; Lepage C; Hautefeuille V; Do Cao C; Smith D; Thuillier P; Cros J; Cadiot G; Walter T; de Mestier L
Eur J Endocrinol; 2023 Dec; 189(6):575-583. PubMed ID: 38039101
[TBL] [Abstract] [Full Text] [Related]
15. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
[TBL] [Abstract] [Full Text] [Related]
16. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study.
Debets P; Dreijerink KMA; Engelsman A; Dahele M; Haak HR; Steenaard RV; Kapiteijn E; Corssmit E; Menke-van der Houven van Oordt CW
Eur J Cancer; 2024 Jan; 196():113424. PubMed ID: 37977106
[TBL] [Abstract] [Full Text] [Related]
17. The effect of cuproptosis-relevant genes on the immune infiltration and metabolism of gynecological oncology by multiply analysis and experiments validation.
Ran XM; Xiao H; Tang YX; Jin X; Tang X; Zhang J; Li H; Li YK; Tang ZZ
Sci Rep; 2023 Nov; 13(1):19474. PubMed ID: 37945610
[TBL] [Abstract] [Full Text] [Related]
18. Radiomics in CT and MR imaging of the liver and pancreas: tools with potential for clinical application.
Berbís MÁ; Godino FP; Rodríguez-Comas J; Nava E; García-Figueiras R; Baleato-González S; Luna A
Abdom Radiol (NY); 2024 Jan; 49(1):322-340. PubMed ID: 37889265
[TBL] [Abstract] [Full Text] [Related]
19. Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms.
Morken S; Langer SW; Sundlöv A; Vestermark LW; Ladekarl M; Hjortland GO; Svensson JB; Tabaksblat EM; Haslerud TM; Assmus J; Detlefsen S; Couvelard A; Perren A; Sorbye H
Br J Cancer; 2023 Dec; 129(12):1930-1939. PubMed ID: 37872405
[TBL] [Abstract] [Full Text] [Related]
20. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y; Ikeda M; Hijioka S; Matsumoto S; Ito T; Aoki T; Furuse J
Invest New Drugs; 2023 Dec; 41(6):777-786. PubMed ID: 37856005
[TBL] [Abstract] [Full Text] [Related]
[Next]
